Additional information
White Powder
1638286-64-2
ACI-030611
179.9-180.7°C
C40H49NO12
735.82
Ambient
2-8°C
Antineoplastic
Pharmaceutical Impurity Standards
1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-amino-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo [11.3.1.03,10.04,7]heptadec-13-ene-2-yl benzoate (De-boc Cabazitaxel)
1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-(Acetyloxy)-15-{[(2R,3S)-3-amino-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-ene-2-yl benzoate(Cabazitaxel Impurity: Amine impurity)
De-boc Cabazitaxel;





![N-ETHYL AZILSARTAN MEDOXOMIL (25 mg) ((5-Methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2′-(4-ethyl-5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)-4-biphenylyl]methyl}-1H-benzimidazole-7-carboxylate)](https://analyticachemie.in/ver-2/wp-content/uploads/uspimage-1.jpg)